Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets
Funds rigorous preclinical validation and early drug discovery against novel Alzheimer's and related-dementia targets, before human trials.
Most Alzheimer's drugs fail because the target they were built against did not hold up. This notice funds rigorously testing a target before committing years to a drug built around it.
Two connected activities are in scope: validating novel drug targets for Alzheimer's disease and Alzheimer's-related dementias, and early-stage discovery of the drugs meant to hit them — small molecules, biologics,…
Preclinical validation of novel drug targets for Alzheimer's disease and related dementias, and early-stage drug discovery of small molecules, biologics and emerging therapeutic modalities against those targets, using the U01 cooperative agreement mechanism.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up